Emblaveo MDR Infections: Evaluating a New Solut...

By HEOR Staff Writer

November 18, 2025

Emblaveo Approved for MDR Gram-Negative Infections Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avib...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC